These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression. Zhang JC; Zhang HJ; Li Y; Jing D; Liu Q; Zhao K; Liu QQ; Zhuang Y; Kang WZ; Sun YT Scand J Infect Dis; 2013 May; 45(5):368-77. PubMed ID: 23186319 [TBL] [Abstract][Full Text] [Related]
8. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A; J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976 [TBL] [Abstract][Full Text] [Related]
9. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. Serrano-Villar S; Gutiérrez C; Vallejo A; Hernández-Novoa B; Díaz L; Abad Fernández M; Madrid N; Dronda F; Zamora J; Muñoz-Fernández MÁ; Moreno S J Infect; 2013 Jan; 66(1):57-66. PubMed ID: 23046968 [TBL] [Abstract][Full Text] [Related]
10. Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy. Zaegel-Faucher O; Bregigeon S; Cano CE; Obry-Roguet V; Nicolino-Brunet C; Tamalet C; Dignat-George F; Poizot-Martin I AIDS; 2015 Jul; 29(12):1505-10. PubMed ID: 26244390 [TBL] [Abstract][Full Text] [Related]
11. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126 [TBL] [Abstract][Full Text] [Related]
13. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S; Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319 [TBL] [Abstract][Full Text] [Related]
14. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function. Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D; Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174 [TBL] [Abstract][Full Text] [Related]
15. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Fidler S; Stöhr W; Pace M; Dorrell L; Lever A; Pett S; Kinloch-de Loes S; Fox J; Clarke A; Nelson M; Thornhill J; Khan M; Fun A; Bandara M; Kelly D; Kopycinski J; Hanke T; Yang H; Bennett R; Johnson M; Howell B; Barnard R; Wu G; Kaye S; Wills M; Babiker A; Frater J; Lancet; 2020 Mar; 395(10227):888-898. PubMed ID: 32085823 [TBL] [Abstract][Full Text] [Related]
16. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Orrell C; Harling G; Lawn SD; Kaplan R; McNally M; Bekker LG; Wood R Antivir Ther; 2007; 12(1):83-8. PubMed ID: 17503751 [TBL] [Abstract][Full Text] [Related]
17. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254 [TBL] [Abstract][Full Text] [Related]
18. HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy. Leth S; Nymann R; Jørgensen S; Olesen R; Rasmussen TA; Østergaard L; Denton PW; Tolstrup M; Søgaard OS AIDS; 2016 Mar; 30(5):713-21. PubMed ID: 26595541 [TBL] [Abstract][Full Text] [Related]
19. A higher CD4/CD8 ratio correlates with an ultralow cell-associated HIV-1 DNA level in chronically infected patients on antiretroviral therapy: a case control study. Yue Y; Wang N; Han Y; Zhu T; Xie J; Qiu Z; Song X; Li Y; Routy JP; Wang J; Li T BMC Infect Dis; 2017 Dec; 17(1):771. PubMed ID: 29246197 [TBL] [Abstract][Full Text] [Related]
20. Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment? Girard PM; Nelson M; Mohammed P; Hill A; van Delft Y; Moecklinghoff C AIDS; 2013 Nov; 27(17):2759-63. PubMed ID: 23842127 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]